CeriBell (CBLL) said Wednesday its point-of-care electroencephalogram system has received full Federal Risk & Authorization Management Program, or FedRAMP, High authorization from the US government, which is granted to organizations that meet the highest cybersecurity standards.
The company said the designation allows its solution to be adopted across federal healthcare systems, expanding access to rapid diagnosis of non-convulsive seizures, particularly for US veterans and other high-risk patients.
Shares of CeriBell were down 3.4% in recent trading.
Price: 15.81, Change: -0.55, Percent Change: -3.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.